<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18452">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02083510</url>
  </required_header>
  <id_info>
    <org_study_id>13-6293</org_study_id>
    <secondary_id>1UL1TR001114-01</secondary_id>
    <nct_id>NCT02083510</nct_id>
  </id_info>
  <brief_title>Apolipoprotein CIII Reduction Via Colchicine</brief_title>
  <official_title>A Translational Study to Understand the Mechanism of Apolipoprotein CIII Reduction Via Colchicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scripps Translational Science Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial will be to determine an effect-size for the administration of chronic
      low-dose colchicine in the reduction of serum levels of triglycerides (TG), very-low density
      lipoproteins (VLDL), and apolipoprotein CIII (apoCIII) in human subjects over a period of
      4-6 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this proposal will be to show, in a translational fashion, a relationship between
      colchicine and reduction of factors affecting triglyceride metabolism, especially apoCIII
      and VLDL levels.  We envision colchicine as playing a role in identifying and elucidating a
      new mechanism for lowering TG levels, which may have a great impact on targeting patients
      who have not met non-HDL goals according to Adult Treatment Panel III (ATPIII guidelines) or
      at risk for hypertriglyceridemia-induced pancreatitis [11].  We will accomplish this by
      conducting a prospective cohort clinical trial of low-dose colchicine in
      hypertriglyceridemic patients to assess percent (%) reduction of apoCIII, VLDL, and TG.
      Secondary endpoints will be to observe the effects of colchicine on apoA, apoB, HDL,
      low-density lipoprotein (LDL), and total cholesterol (TC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Reduction in ApoCIII levels</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of triglycerides and very low density lipoprotein (VLDL) levels</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of Apolipoprotein A and Apolipoprotein B via Vertical Auto Profile (VAP)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <condition>Gout</condition>
  <condition>Pericarditis</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be enrolled with either gout/pericarditis or hypertriglyceridemia, have VAP and Apolipoprotein CIII levels at baseline, administer Colchicine for 6 weeks with reassessment of Apolipoprotein CIII and VAP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <arm_group_label>Colchicine</arm_group_label>
    <other_name>Colcrys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute new-onset pericarditis or recurrent pericarditis (≥2 following criteria)

               -  Sharp and pleuritic chest pain improved or relieved by sitting up and leaning
                  forward

               -  A pericardial friction rub

               -  Electrocardiogram (EKG) findings of diffuse ST-segment elevations or PR
                  depression

               -  New or worsening pericardial effusion visualized on echocardiogram.

        OR

        •Acute gouty arthritis (according to the ACR; ≥1 of following criteria:

          -  Joint fluid containing urate crystals

          -  Tophus proved to contain urate crystals by chemical means

          -  Polarized light microscopy

          -  Presence of six of the following in the absence of crystal identification:

          -  &gt;1 attack of acute arthritis

          -  Maximum inflammation developed in 1 day

          -  Monoarthritis attack

          -  Redness observed over joints

          -  1st metatarsal joint painful or swollen

          -  Unilateral 1st metatarsal joint attack

          -  Unilateral tarsal joint attack

          -  Tophus (suspected)

          -  Hyperuricemia

          -  Asymmetric swelling within a joint visible on physical examination or radiography

          -  Subcortical cysts without erosions visible on radiography

          -  Monosodium urate monohydrate microcrystals in joint fluid during attack

          -  Joint fluid culture negative for organisms during attack.

        If N &lt; 10 after 3 weeks of trial initiation, then employ enrollment strategy #2

        Enrollment strategy #2:

          -  History of hypertriglyceridemia (TG ≥ 150 mg/dL) AND

          -  Age ≥ 18 years old

          -  Capable of providing informed consent

          -  Capable of taking Colchicine 0.6-1.2 mg/day orally for 6 weeks

          -  Capable of providing a blood sample

        Exclusion Criteria:

          -  Colchicine use &lt; 8 weeks from baseline VAP panel

          -  Pregnant or female of child bearing age

          -  On corticosteroid therapy or corticosteroid use &lt; 4 weeks from baseline VAP panel

          -  History of statin myopathy or hepatotoxicity

          -  History of colchicine intolerance or hypersensitivity

          -  Severe end-stage renal disease (eGFR ≤ 20 mL/min/1.73 m2) or requiring dialysis

          -  Hepatic Impairment (Child-Pugh class B or C)

          -  Myopericarditis (If TnI is elevated on presentation of acute pericarditis)

          -  Inflammatory Bowel Disease

          -  Tuberculous, neoplastic, or purulent pericarditis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Schultz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Translational Science Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Scripps Research Institute</investigator_affiliation>
    <investigator_full_name>Peter G. Schultz, PhD</investigator_full_name>
    <investigator_title>Prinicpal Investigator</investigator_title>
  </responsible_party>
  <keyword>Colchicine</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <keyword>Apolipoprotein CIII</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Pericarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
